サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：化学療法誘発性貧血の世界市場-2023-2030
市場調査レポート
商品コード
1290353

化学療法誘発性貧血の世界市場-2023-2030

Global Chemotherapy-Induced Anemia Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
化学療法誘発性貧血の世界市場-2023-2030
出版日: 2023年06月12日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

市場概要

化学療法誘発性貧血の世界市場規模は、2022年に22億4,000万米ドルに達し、2030年には38億9,350万米ドルに達し、有利な成長が予測されています。化学療法誘発性貧血市場は、予測期間（2023-2030年）に7.2%のCAGRを示すと予測されています。

貧血は、体内の赤血球の状態が正常値を下回る状態です。赤血球が不足すると、身体の各部位に十分な酸素が供給されなくなります。その結果、体の各部位が必要な機能を果たせなくなり、問題が発生します。体内で十分な赤血球が作られなかったり、赤血球が排出されたりすると、貧血を発症します。また、血流から多くの血液を失うと、貧血を引き起こす可能性があります。貧血は、がんやがん治療による典型的な副作用であり、特に化学療法を受けている人に顕著です。

市場力学

がん患者の増加が、予測期間中の世界の化学療法誘発性貧血市場を牽引しています

がんの症例の増加が、予測期間中の世界の化学療法誘発性貧血市場を牽引しています。例えば、2022年に世界で発表された調査研究によると、GLOBOCAN 2020に登録されているように、評価された1930万人のケースと1000万人以上の死亡は、がんが原因でした。これらの患者全体の中で、世界的に典型的に検出されたがんの発生率は、女性の前立腺がん（141万人、7.3％）、肺がん（221万人、11.4％）、乳がん（226万件、11.7％）でした。

老年人口が世界の化学療法誘発性貧血市場に前向きな成長機会を提供しています

がんは年齢に関係なく増殖する可能性がありますが、高齢になるにつれて、多くの種類のがんがより典型的になっていきます。これは、年齢を重ねるにつれて、体の細胞が傷つくためです。この劣化が加齢とともに進行し、がんを発生させることがあるのです。このように、老年人口の増加は、今後数年間、世界市場に有望な成長機会をもたらすことになります。例えば、国連の「World Population Prospects 2022」によると、80歳以上の人口は2022年の1億5700万人から2050年には4億5900万人と3倍に増加すると予想されています。

COVID-19の影響分析

COVID-19の分析には、Pre-COVIDシナリオ、COVIDシナリオ、Post-COVIDシナリオがあり、価格ダイナミクス（パンデミック時およびパンデミック後の価格変動とCOVID前のシナリオとの比較）、需給スペクトル（取引制限、封鎖およびその後の問題による需要と供給のシフト）、政府の取り組み（政府機関による市場、セクター、産業の活性化に関する取り組み）、メーカーの戦略的取り組み（COVID問題を軽減するためのメーカーの取り組み）についても解説する予定です。

ロシア・ウクライナ紛争影響分析

ウクライナの戦乱により、数百万人の人々が無秩序な生活を送る中、多くのウクライナ人が国家の西部地域に逃れなければならず、欧州や国外に難民となっています。その中には、がん患者も含まれており、極度の病気と亡命という壮絶なワンツーフォースに遭遇しました。また、ウクライナのがん専門病院が襲撃されるなどして閑古鳥が鳴く中、国境を越えたウクライナ人患者は、制裁とインフレに見舞われ、治療の先行きすら不透明な状況に陥っています。

世界同時不況の影響分析

ヘルスケア業界は不況に全く無縁というわけではありません。しかし、その本質的な性質から、他の業界よりもうまく対処しています。しかし、インフレ率が上昇を続ける中、景気後退の危機は市場を脅かしています。世界の先進諸国における高インフレは、過去2年間における一般的なコスト高騰をもたらし、景気後退の継続に対する緊張感を高めています。一般的な購買意欲の累積的な悪化は、特に成長経済に影響を及ぼすと予想され、多くの点で有益であると考えられます。

目次

第1章 調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 調査活動
      • がん罹患率の増加
    • 抑制要因
      • 規制当局の厳しさ
    • 機会
    • 政府の取り組み
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • 法規制分析
  • 価格分析
  • 特許分析
  • PEST分析

第6章 COVID-19の分析

第7章 ロシア・ウクライナ戦争分析

第8章 世界同時不況の分析

第9章 疾患タイプ別

  • 軽度貧血
  • 中等度貧血
  • 重度貧血

第10章 治療法別

  • 赤血球輸血
  • 赤血球造血刺激因子製剤（ESA）
  • 鉄剤の補充

第11章 薬剤別

  • エポゲン注射液
  • プロクリット注射
  • アンドロキシ経口剤
  • アランエスプ注射液
  • エポエチンアルファ注射液
  • その他

第12章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 外来手術センター
  • がん研究センター
  • がんリハビリテーションセンター

第13章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第14章 競合情勢

  • 競合シナリオ
  • 市場シェア分析
  • M&A（合併・買収）分析

第15章 企業プロファイル

  • Dr. Reddy's Laboratories Ltd.
    • 企業概要
    • 疾患別ポートフォリオと内容
    • 財務概要
    • 主な発展状況
  • Pfizer Inc
  • Panacea Biotec Limited
  • SBI PHARMACEUTICALS CO., LTD
  • Tolero Pharmaceuticals, Inc.
  • Vifor Pharma AG
  • Therapure Biopharma Inc.
  • PharmaEssentia Corp.
  • PhytoHealth Corp
  • UBI Pharma Inc

第16章 付録

目次
Product Code: PH1420

Market Overview

The Global Chemotherapy-Induced Anemia Market size reached USD 2,240 million in 2022 and is projected to witness lucrative growth by reaching up to USD 3,893.5 million by 2030. The chemotherapy-induced anemia market is expected to exhibit a cagr of 7.2% during the forecast period (2023-2030).

Anemia is a condition in which the body's status of red blood cells goes below normal. When the body does not contain adequate RBCs, the body parts do not acquire sufficient oxygen. As a consequence, they cannot perform in the manner they require to and induce issues. Individuals conceive anemia if their body does not produce adequate RBCs or eliminates them. Thus, individuals can even induce anemia if they lose too much blood from their bloodstream. Anemia is a typical side consequence of cancer and cancer therapy, specifically true for individuals accepting chemotherapy.

Market Dynamics

The Growing Cases Of Cancer Are Driving The Global Chemotherapy-Induced Anemia Market In The Forecast Period.

The growing cases of cancer are driving the global chemotherapy-induced anemia market during the forecast period. For instance, according to a research study published in 2022 worldwide, an assessed 19.3 million cases and over 10 million demises were because of cancer as registered in GLOBOCAN 2020. Among these entire patients, the incidence of typically detected cancers globally were female prostate cancers (1.41 million, 7.3%), lung (2.21 million, 11.4%), and breast (2.26 million cases, 11.7%).

The Geriatric Population Is Providing The Global Chemotherapy-Induced Anemia Market With Prospective Growth Opportunities.

Cancer can grow at any age, despite as individuals get older, a majority of kinds of cancer become more typical. This is because the body's cells can get harmed over the period. This deterioration can then produce up as individual ages, and can frequently yield cancer. Thus, the growing geriatric population presents the global market with prospective growth opportunities in the upcoming years. For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine War Impact Analysis

As the warfare in Ukraine released disorder and uprooted millions of individuals, numerous Ukrainians had to escape to the western region of the nation and became refugees in Europe and outside. Among them were individuals with cancer, who encountered a fierce one-two force of extreme sickness and exile. And while cancer hospitals in Ukraine are being deserted or even attacked, Ukrainian patients across the boundary, struck by sanctions and inflation, even encounter an indefinite future for their care.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession as the high inflation in developed countries worldwide has transpired in a general cost surge over the past two years. The cumulatively deteriorating general purchasing control is anticipated to affect growing economies particularly and is considered helpful in numerous ways.

Segment Analysis

The global chemotherapy-induced anemia market is segmented based on disease type, treatment type, drug type, end-user, and region.

The Erythropoiesis-Stimulating Agents (ESAs) Treatment Type Segment Is Estimated To Hold A 34.1% Share Of The Global Market By 2030.

The erythropoiesis-stimulating agents (ESAs) treatment type segment is estimated to hold about 34% of the total chemotherapy-induced anemia market by 2030, owing to the increasing clinical research activities. For instance, in May 2023, FibroGen, Inc., a top biopharmaceutical enterprise committed to finding, creating, and selling a product line of first-in-class therapeutics, and its associate, FibroGen (China) Medical Technology Development Co., Ltd. informed favorable topline information from corporation's Phase 3 clinical trial of roxadustat for the treatment of anemia in people taking coexisting chemotherapy drug for non-myeloid malignancies in China.

Geographical Analysis

Europe is Estimated To Hold The Second-Largest Share Of The Global Chemotherapy-Induced Anemia Market During The Forecast Period.

Owing to the growing number of cancer deaṭhs and measures to battle against cancer, Europe is estimated to hold about 26.6% of the global chemotherapy-induced anemia market by 2030. For instance, according to the 2022 edition of Health at a Glance, cancer is the second largest basis for death in the European Union following cardiovascular conditions. Over 30-50% of cancer individuals' deaths are avertable, and mortality can also be lowered via premature identification and the essential better punctual, and efficacious cures. Europe's Beating Cancer Plan aims to lower the burden of cancer and handle cancer-related inequalities among and in the governments, with struggles to aid, harmonize and satisfy the activities of Member States.

Competitive Landscape

The major global players in the market include: Dr. Reddy's Laboratories Ltd, Pfizer Inc, Panacea Biotec Limited, SBI PHARMACEUTICALS CO., LTD, Tolero Pharmaceuticals, Inc., Vifor Pharma AG, Therapure Biopharma Inc., PharmaEssentia Corp., PhytoHealth Corp, and UBI Pharma Inc among others.

Why Purchase the Report?

  • To visualize the global chemotherapy-induced anemia market segmentation based on disease type, treatment type, drug type, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of chemotherapy-induced anemia market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global chemotherapy-induced anemia market report would provide approximately 53 tables, 54 figures, and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by Drug Type
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Research Activities
      • 4.1.1.2. Growing Cancer Prevalence
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Authorities
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. PEST Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. By Disease Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.1.2. Market Attractiveness Index, By Disease Type
  • 9.2. Mild Anemia
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Moderate Anemia
  • 9.4. Severe Anemia

10. By Treatment Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.1.2. Market Attractiveness Index, By Treatment Type
  • 10.2. RBC Transfusions
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Erythropoiesis-stimulating agents (ESAs)
  • 10.4. Iron Supplementation

11. By Drug Type

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.1.2. Market Attractiveness Index, By Drug Type
  • 11.2. Epogen Injection
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Procrit Injection
  • 11.4. Androxy Oral
  • 11.5. Aranesp injection
  • 11.6. Epoetin Alfa Injection
  • 11.7. Others

12. By End User

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.1.2. Market Attractiveness Index, By End User
  • 12.2. Hospitals
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Specialty Clinics
  • 12.4. Ambulatory Surgical Centers
  • 12.5. Cancer Research Centers
  • 12.6. Cancer Rehabilitation Centers

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.7.1. The U.S.
      • 13.2.7.2. Canada
      • 13.2.7.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.7.1. Germany
      • 13.3.7.2. The U.K.
      • 13.3.7.3. France
      • 13.3.7.4. Italy
      • 13.3.7.5. Spain
      • 13.3.7.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.7.1. Brazil
      • 13.4.7.2. Argentina
      • 13.4.7.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.7.1. China
      • 13.5.7.2. India
      • 13.5.7.3. Japan
      • 13.5.7.4. Australia
      • 13.5.7.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Dr. Reddy's Laboratories Ltd.
    • 15.1.1. Company Overview
    • 15.1.2. Disease Type Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Pfizer Inc
  • 15.3. Panacea Biotec Limited
  • 15.4. SBI PHARMACEUTICALS CO., LTD
  • 15.5. Tolero Pharmaceuticals, Inc.
  • 15.6. Vifor Pharma AG
  • 15.7. Therapure Biopharma Inc.
  • 15.8. PharmaEssentia Corp.
  • 15.9. PhytoHealth Corp
  • 15.10. UBI Pharma Inc

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us